PKCα Antibody, anti-human, REAfinity™
Synonyms: PRKCA, AAG6, PKC-alpha, PRKACA, PKC-A
RECOMBINANT
Clone:
REA156 | 3/PKCa
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
ICFC, MICS, IF, IHC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for PKCα Antibody, anti-human, REAfinity™

Intracellular flow cytometry applications
APC
PE
PerCP-Vio 700
Recommended dilution:
1:50
Remark:
The antibody is suited for staining of formaldehyde-fixed cells.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-132-430, 130-132-466
Description:
Human peripheral blood mononuclear cells (PBMCs) were either left unstimulated (right peak) or stimulated with 100 ng/mL phorbol 12-myristate 13-acetate (PMA) for 24 hours. The cells were fixed and permeabilized with the Cell Signaling Buffer Set A and stained with Anti-PKCα antibodies. Cells were then analyzed by flow cytometry using the MACSQuant® Analyzer. Lymphocytes were pre-gated for the analysis. Cell debris were excluded from the analysis based on scatter signals. As shown in the histogram, PMA stimulation of lymphocytes results in decreased PKCα expression.

Application image
MICS (MACSima Imaging Cyclic Staining) applications
APC
PE
Fixation:
frozen – Acetone
Species tested:
mouse
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Compatible applications:
IF, IHC
Conjugate:
APC
Used products:
130-132-430, 130-132-466
Testing grade:
Fixation:
FFPE
Species tested:
human
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Compatible applications:
IF, IHC
Conjugate:
APC
Used products:
130-132-430, 130-132-466
Testing grade:
Fixation:
frozen – Acetone
Species tested:
human
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Compatible applications:
IF, IHC
Conjugate:
APC
Used products:
130-132-430, 130-132-466
Testing grade:
Specifications for PKCα Antibody, anti-human, REAfinity™
Overview

Clone REA156 recognizes the PKCα antigen regardless of its phosphorylation status. It has been reported to cross-react with PKCβ. PKCα is a serine- and threonine-specific protein kinase that can be activated by calcium and the second messenger diacylglycerol. It plays a role in many different cellular processes, such as cell adhesion, cell transformation, cell cycle checkpoint, and cell volume control. PKCα is highly expressed in a number of cancer cells where it can acts as a tumor promoter and it is implicated in malignant phenotypes of several tumors such as gliomas and breast cancers. Knockout studies in mice suggest that this kinase may be a fundamental regulator of cardiac contractility and Ca2+ handling in myocytes.

Additional information: Clone REA156 displays negligible binding to Fc receptors.

Alternative names

PRKCA, AAG6, PKC-alpha, PRKACA, PKC-A

Detailed product information

Technical specifications

Clone
REA156
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (I), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human, mouse, rat, other
Cross-reactivity
mouse, rat, dog, chicken
Antigen
PKCα
Molecular mass of antigen [kDa]
77
Distribution of antigen
other
Entrez Gene ID
RRID
AB_2889730, AB_2653211, AB_2653212, AB_2889729

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for PKCα Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

Citations for PKCα Antibody, anti-human, REAfinity™
Publications
  1. Koivunen, J. et al. (2006) Protein kinase C (PKC) family in cancer progression. Cancer Lett. 235 (1): 1-10
  2. Finkenzeller, G. et al. (1990) Sequence of human protein kinase C alpha. Nucleic Acids Res. 18 (8): 2183
  3. Xu, H. et al. (2008) Protein kinase C alpha promotes angiogenic activity of human endothelial cells via induction of vascular endothelial growth factor. Cardiovasc. Res. 78 (2): 349-355

You have previously chosen International as your location.
What do you want to do?